Exchange: OTC·Updated 03:55 PM EST

ADAPY Adaptimmune Therapeutics Plc - ADR

$0.03
$0.001
(3.23%)
Today
Reported EarningsAug 13
Mkt Cap$7.95M
Vol915,181.00

About ADAPY

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
48

Neutral Sentiment

How do you feel about ADAPY?

manny11419
$ADAPY If indeed we are a due MS for BLA acceptance before EOY and USW is responsible for submitting it, thats a crazy agreement. They could delay it after December 31, and save that MS.
3
3
US_Bull
$ADAPY Already this is definitely a leak now confirmed IMO 2,5 million last week and now already traded 889k after 17 minutes.
1
15
US_Bull
$ADAPY Another one and this is even closer than the Marketing position posted four days ago. Currently Kite is not involved with allogenenic cel therapy look below that is one of the preferred qualification. Posted yesterday.
3
7
duepillagence
$ADAPY Don't get discouraged (or defensive lol) by lengthy clinical trials (astellas just paid $ 1.34 bill for a compound that haven't even made pre clinicals much less established IND readiness) so I highly doubt they'll wait until full TILIL7 trial completion before making a move IN FACT I wouldn't be surprised a move is made PRE ph1 read-out !!!!
1
12
US_Bull
$ADAPY Sandra's oral presentation is locked so only members can get access to it the full cohort from the SPEARHEAD study I see us getting closer to 5-7 plus cents in short timeframe with another 15 million in the bank when Lete-cel BLA is accepted and FDA approved later on likely sometime in Q2, 2027 if we are not sold by then.
1
8
bumperlogos
$ADAPY their research helped bring the first engineered T-cell therapy for a solid tumor to patients. With PRAME- and CD70-directed programs and an allogeneic platform in its next chapter, there’s real scientific potential, and upside here, whether that development moves forward independently or with partners.
2
7
MuzunguZanz
$ADAPY Should I get more shares? Pharma is not my forte and reading the posts is like reading hieroglyphics. Are we close to making some money. Serious question.
1
8
manny11419
$ADAPY From what the more knowledgeable posters have posted..it seems our micro-micro stock has the potential to generate some unheard of final return....and if we do have a very green Christmas...kudos to all of you.
11
duepillagence
$ADAPY Oh btw -IL-7 the gene = (not proprietary) anyone can own it.. -IL-7 the vector = (proprietary specific to adaptimmune due to engineering) takes 3 to 5 years to engineer.. -Astellas just paid $ 1.34 bill for It's relative IL-12 as a license agreement:
1
8
Pitt86
$ADAPY The deadline for the FDA to accept the BLA review for lete-cel is December 31, 2026; otherwise, the $5 million payment will not be made.
1
4
PaidPiper
$ADAPY falling alongside the market ≠ underperforming against the market. Stay patient, you won't get proof of progress, you'll get proof of partnership or sale
10
readbet
$ADAPY may trade like a penny stock on the OTC, but will sell like an auctioned Cadillac.
1
7
readbet
$ADAPY perhaps not 12/04, maybe soon.. Lilly leveraged Orna’s circular RNA engine to pivot across oncology and autoimmune indications, Gilead/Kite could port Adaptimmune's membrane-bound IL-7 and CD8a homodimer co-receptor cassettes directly into its existing commercial autologous pipelines, and we should not forget the Allogeneic hIPSC Scale Engine: Bypassing patient-by-patient autologous manufacturing via an automated human induced pluripotent stem cell bioreactor differentiation engine is the Lilly Orna analogous tie, so combined could exceed $1.4B. In my opinion, you could be surprised with something more like$1.4 + $1.8 for ~$3.2B premium deal when the time comes.
9
duepillagence
$ADAPY Its still Gilead/Kite imho because of the job posting and: * "theres nothing in our most recently updated disclosures that hints at TCR interests" BUT ALSO * "Our secret activity shows PRAME IP purchases and PRAME is only accessed through TCRs"..
1
6
Mogeyman
$ADAPY Watch out y'all! Stinky doesn't hold any shares (but used to (naturally 🙄)). He's just here to troll because he was in routine regular contact with prior management and they lied to him. 🥲 Happy Friday.
2
3
Dipshit101
$ADAPY another bull day !!! Let it continue as I hope other meat heads seen what happen yesterday and will jump in
9
readbet
$ADAPY playing into Gilead or KITE or similar hypothesis using guided AI risk - reward model under reframe away from OTC perceptions..
9
PaidPiper
$ADAPY Adap announced its USWM asset sale on July 28th 2025. The transaction closed July 31st. That was possible because the strategic review and negotiations had already taken place. So this 2 month window before the end of the fiscal year and the end of chris hills contract is sufficient enough time to announce and close if most of the work has already been completed..
9
PaidPiper
$ADAPY the PT is 1-5 bucks. Anything below that would be "giving it away" and anything above we'd be considered lucky.
8
Ttubular
$ADAPY let’s all face the facts here we are in tight trading range until a partnership or BO. Doesn’t matter what the market does or the bio sector. Case closed That is my opinion from what I see.
7

Advertisement|Remove ads.